Correction

For the following articles, the affiliations for author Prof. Paul Emery, should be given as follows: Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK. We regret the error.

Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. *J Rheumatol* 2009;36:1256-64;

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. *J Rheumatol* 2009;36:1429-41;

Conaghan PG, Bird P, McQueen, F, et al. The OMERACT MRI Inflammatory Arthritis Group: Advances and future research priorities. *J Rheumatol* 2009;36:1803-5;

Østergaard M, Conaghan PG, O'Connor P, et al. Reducing invasiveness, duration, and cost of MRI in rheumatoid arthritis by omitting IV contrast injection — Does it change the assessment of inflammatory and destructive joint changes by the OMERACT RAMRIS? *J Rheumatol* 2009;36:1806-10;

Østergaard M, McQueen F, Wiell C, et al The OMERACT psoriatic arthritis MRI scoring system (PsAMRIS): Definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for psoriatic arthritis hands. *J Rheumatol* 2009;36:1816-24;

Haque S, Gordon C, Isenberg D, et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. *J Rheumatol* 2010;37:322-9;

van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials *J Rheumatol* 2010;37:558-67.

doi:10.3899/jrheum.emeryC1